×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!

PAREXEL Simplifies Access to Knowledge

June 20, 2018
A new report by the Economist Intelligence Unit (EIU) and commissioned by PAREXEL International Corporation reveals that new innovations in drug development have a positive impact on clinical trial timelines, likelihood of market launch, and inclusion on selected payer formularies.
Previous Video
PAREXEL CMO Sean Gallimore Introduces the EIU
PAREXEL CMO Sean Gallimore Introduces the EIU

Next Video
How will payers receive innovative trial designs?
How will payers receive innovative trial designs?

As costs continue to rise and downward reimbursement price pressure increases, the industry is exploring ne...